First Hawaiian Bank Cuts 39.4% of its Holdings in Halozyme Therapeutics,
July 5, 2023
🌧️Trending News
Halozyme Therapeutics ($NASDAQ:HALO), Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative products focused on the treatment of cancer and other serious diseases. First Hawaiian Bank, one of the largest financial institutions in Hawaii, recently cut its holdings in Halozyme Therapeutics by 39.4% in the first quarter of this year. This move follows a larger trend of investors reducing their exposure to high-risk biotech stocks. Despite this decrease in ownership, Halozyme Therapeutics continues to develop and commercialize its technologies to improve the lives of patients with serious diseases.
The company has recently expanded its collaborations with several large pharmaceutical companies, including Bristol-Myers Squibb, Merck and Eli Lilly. The company also maintains partnerships with several other companies to further its research and development efforts. Overall, while First Hawaiian Bank has reduced its ownership stakes in Halozyme Therapeutics, Inc., the company continues to make progress in its mission to develop innovative treatments for cancer and other serious diseases.
Analysis
GoodWhale has analyzed HALOZYME THERAPEUTICS‘s financials and determined that it is a high risk investment in terms of financial and business aspects. Our Risk Rating takes into account many factors such as the company’s balance sheet, cashflow statement, and financial journal. Our analysis has detected 3 risk warnings that investors should be aware of. We encourage you to register with us to get more details about HALOZYME THERAPEUTICS’s financials and the risks associated with investing in this company. With our comprehensive analysis, you will have the necessary information to make an informed decision on whether to invest or not. More…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Halozyme Therapeutics. More…
| Total Revenues | Net Income | Net Margin |
| 704.98 | 181.64 | 25.7% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Halozyme Therapeutics. More…
| Operations | Investing | Financing |
| 279.28 | -497.86 | 197.13 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Halozyme Therapeutics. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 1.7k | 1.63k | 0.5 |
Key Ratios Snapshot
Some of the financial key ratios for Halozyme Therapeutics are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 62.5% | 21.2% | 35.0% |
| FCF Margin | ROE | ROA |
| 37.4% | 130.7% | 9.1% |
Peers
The Company’s enzyme-based product candidates target the tumor microenvironment, enabling the delivery of cancer drugs directly to the site of the tumor. Halozyme has four product candidates in clinical development, PEGPH20, Hylenex, HALO-102 and HALO-201. Keymed Biosciences Inc, Verona Pharma PLC, Xencor Inc are Halozyme’s competitors in the biopharmaceutical market.
– Keymed Biosciences Inc ($SEHK:02162)
Keymed Biosciences Inc is a biopharmaceutical company that focuses on the development and commercialization of novel therapeutics for the treatment of cancer and other serious diseases. The company’s market cap is 12.95B as of 2022 and has a ROE of -4.34%. Keymed Biosciences Inc’s products are designed to target key drivers of disease progression and to provide patients with new treatment options. The company’s lead product, KEY-184, is a first-in-class, orally-available small molecule inhibitor of the MDM2 oncoprotein.
– Verona Pharma PLC ($NASDAQ:VRNA)
Verona Pharma PLC is a pharmaceutical company that focuses on the development of drugs for the treatment of respiratory diseases. The company has a market cap of 790.27M as of 2022 and a Return on Equity of -28.69%. Verona Pharma PLC is headquartered in London, United Kingdom.
– Xencor Inc ($NASDAQ:XNCR)
Xencor Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases. The company’s market cap as of 2022 is 1.64B with a ROE of 4.05%. Xencor is currently working on several clinical-stage programs including XmAb5871 for the treatment of B-cell malignancies, autoimmune diseases, and asthma.
Summary
This indicates that the bank has shifted its focus away from the company, possibly due to weakening performance or lack of potential in the biotechnology sector. For investors looking to gain exposure to Halozyme, it is important to conduct a thorough analysis of the financials, management team, industry trends, and competitive landscape. This can help investors make better decisions and optimize their returns in the long run.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
